Public Health and Research News

HOUSTON, TX–(Marketwire – December 8, 2010) –  Plunkett Research, Ltd. has released its newest market research and competitive analysis report, Plunkett’s Health Care Industry Almanac, 2011 edition, which identifies and analyzes major trends shaping the health care industry.

According to Jack W. Plunkett, CEO of Plunkett Research, Ltd., “While total health expenditures continue to grow in the U.S., health care is spreading rapidly in emerging nations like India and China.”

Major trends affecting the Health Care Industry analyzed in Plunkett’s report include:

• Continued rise in health care costs.
• Employers push health care costs onto employees.
• Medicare and Medicaid spending continue to surge.
• Health Care Reform Act of 2010 set to bring big changes.
• Major drug patents expire while generic growth continues.
• Quality of care and health care outcomes data become available online.
• Obesity sparks government action.
• Health care thrives offshore, medical tourism grows.
• Disease management programs take root.
• Health care industry to grow rapidly in China and India.

“Eventually, innovative health practices and technologies developed for lower-income nations will migrate to the U.S., helping to contain costs,” said Jack Plunkett.

A complete report with detailed industry trends and statistics analysis is provided in Plunkett’s Health Care Industry Almanac, 2011 edition. This informative reference book gives you the competitive intelligence you need, with a detailed industry overview, industry analysis and market research. Plus, thousands of contacts for business and industry leaders, industry associations and industry sites, as well as statistical tables, an industry glossary and thorough indexes — everything you need all in one value-priced, easy-to-use package.

A complimentary video of Plunkett discussing these trends is now available on the Plunkett Research website, as well as YouTube, and an Introduction to the Health Care Industry can be viewed at Plunkett’s website. 

About Plunkett Research, Ltd.
Plunkett Research is a leading provider of industry trends analysis and market research. Our reports and data services are used by the world’s top corporations, consultants, universities, libraries and government agencies. Plunkett’s products save time and effort when you need competitive intelligence, market research or marketing data. For more from Plunkett Research, become a Fan on Facebook and subscribe to our YouTube channel.

Click here to see all recent news from this company

DENVER, CO–(Marketwire – December 8, 2010) – Like the scale in the doctor’s office, the numbers can be daunting. Similarly, the statistics that reveal an increasingly overweight America — 67 percent and rising — are sending shivers down the spine of this nation’s health care system, especially in corporate America where the costs of keeping employees healthy are threatening both the bottom line and the country’s economic future.

Today it costs employers an estimated $13,000 annually to provide premium health care benefits for a typical employee and his or her dependents, and that figure has gone up 10 percent each year for the past decade. Of that annual amount, almost $10,000 is paid by the employer. 

In an attempt to stem the tide, Denver-based incentaHEALTH has focused on one of the biggest drivers of health care costs: obesity. Overweight and obese employees incur over $1,500 in additional costs for the employer each year. In response, incentaHEALTH has developed a unique program that pays employees and their families to lose weight, stay healthy and remain productive. Blending technology, ingenuity, medical expertise, and employer resources, it is designed to encourage greater participation by employees in typical company health plans.

According to Todd McGuire, Chief Technology Officer, who co-founded the company in 2002 with CEO Jack Rule, the idea for incentaHEALTH was developed after discovering that among the most pressing issues facing the business world at the time were runaway health care costs and obesity.

“In 2002 we weren’t happy with the wellness programs used by the rest of the industry, so we created our own,” McGuire said. “Our technology authenticates health outcomes instead of relying on people to self-report. Since we are paying cash incentives, you don’t want somebody to send a friend down to weigh in for them.”

The centerpiece of the incentaHEALTH system is the patented HEALTHspot kiosk which, when strategically placed throughout a company’s facilities, provides:

• Automated biometric measurements of weight, blood pressure and body mass index (BMI) using authenticated measurements (not self-reported)
• Instant feedback to participants and program administrators
• 24-hour, low cost operation and remote maintenance
• Enhanced privacy
• Full-body digital imaging to keep track of participant progress and create a visual progress report
• Complete and accurate electronic records for both employee and employer

Supporting the kiosks, the program uses a variety of communication tools to reach all employees and motivate them to participate. Says McGuire, “Behavior change is a daily battle. It won’t occur with an occasional newsletter. A better approach is a daily coaching plan using emails and text messages that shows employees and their dependents exactly how to eat and exercise.” The program incorporates onsite kickoff sessions and printed support materials to reach employees without email access.

“The national view of health and wellness has matured significantly since we started our business,” said McGuire. “After extensive research of the problem and conducting surveys of the workforce, the wellness industry has found that people are inactive, overweight, have high blood pressure and are not eating properly. Employers are now demanding programs that result in real behavioral changes to tackle these issues.”

“Historically, employers have offered $50 to employees just to sign up for a wellness program, whether they used it or not,” he added. “What we do is shift from an incentive for participating to an incentive for measured performance. For example, if an employee signs up for our program and achieves a 15 percent weight loss, they will get paid, in actual dollars on a brightly colored check, when they weigh in at the HEALTHspot kiosk every 90 days.” The program pays incentives ranging from $15 to $150 per quarter to all employees based on the amount of weight they lose, so every level of success is rewarded.

So far, the incentaHEALTH approach to corporate wellness is working. Organizations across the globe are signing up — companies like Jackson National Life Insurance Co., Virginia Tech, Kaiser Permanente, Long Beach Memorial Medical Center, Accident Fund Insurance Company of America, U.S. Department of Health and Human Services, and others that are concerned about their employees’ health.

“incentaHEALTH has become an integral part of our overall wellness program, which helps our associates make healthier lifestyle choices,” said Cheng Hsu, benefits manager at Jackson National.

And users are noticing a big difference in their health.

“I’ve lost 70 pounds on this program. I am now eating healthy, watching my portion sizes and exercising,” said one employee participant. “It was a true godsend.”

About incentaHEALTH
incentaHEALTH is an innovative health care technology company based in Denver, Colorado. incentaHEALTH’s fully outsourced, employee weight management program is designed to help organizations reduce their health care costs by offering incentives to employees for improving their health. This is achieved by helping employees manage their weight through the use of interactive email coaching, workplace weigh-ins on private kiosks, and cash rewards for maintaining long term health improvements. For more information, visit www.incentahealth.com.

Click here to see all recent news from this company

NEW YORK, NY and JERUSALEM–(Marketwire – December 7, 2010) – The International Center for Autism Research and Education (ICare4autism), a New York-based charity, announced plans to create the world’s first Global Autism Center on Mt. Scopus in Israel, dedicated to catalyzing breakthrough innovation in autism research and treatment. In a ceremony at Jerusalem‘s City Hall hosted by Mayor Nir Barkat, ICare4autism’s President Joshua Weinstein signed an agreement paving the way for ICare4autism to acquire the campus of Bezalel Academy of Art in 2013, and convert it into a center, housing:

• State-of-the-art autism research facilities to serve as a platform for global collaboration.

• The world’s first university-level school of autism studies, to raise therapeutic standards worldwide.

• A model school, applying the latest research, technology and design to the needs of students across the Autistic Spectrum.

• A foundation to support transformative global collaborations in autism education and treatment.

Joshua Weinstein said, “To tackle the global autism epidemic, we need a community of researchers, educators and advocates that reaches across borders. Our new Center will give us the ability to convene and empower that community.”

Said Dr. Eric Hollander, Chairman of ICare4autism’s Scientific Advisory Council, “The Center will drive the research needed to discover the etiology of autism, ultimately leading to better methods of detection and treatment.”

Said Mayor Barkat, “We welcome ICare4autism’s plan to create a Global Autism Center on Mt. Scopus, and we look forward to the breakthroughs in research that will emanate from its campus to benefit the entire world.”

About Joshua Weinstein, MBA and MA Ed
Mr. Weinstein is the Founder of ICare4autism, which encompasses Shema Kolainu – Hear our Voices School and Center for Children with Autism in New York City, and Tishma – ABA School and Center for Children with Autism in Jerusalem, Israel.

About Dr. Eric Hollander, MD
Dr. Hollander, Chairman of the Advisory Council of ICare4autism, is a renowned psychiatrist on the faculty of Montefiore Medical Center University Hospital of Albert Einstein College of Medicine, former Chair of Psychiatry at the Mt. Sinai School of Medicine and Director of the Seaver and Greater New York Autism Center of Excellence.

id=”nav_links”>

LOS ANGELES, CA–(Marketwire – December 7, 2010) – Announced today, Santa Claus and some very special helpers will be visiting Hair Fairies salons (www.hairfairies.com) nationwide. Santa will be on site every Saturday in December through Christmas to deliver cheer, take photos, listen to wish lists and hand out special treats. The holiday season is upon us and nobody wants it ruined by having to deal with head lice. So, if these bugs happen to find their way into your home, what better way to get rid of them then at one of Hair Fairies unique salons, with the added benefit of meeting jolly ol’ St. Nick. The friendly technicians will work their magic with special techniques and 100% natural, non-toxic products. They will also be discounting many of their all natural Nit-Zapping™ head lice treatment products and up to 50% off your final treatment.

“The holiday season is an important time of year and we want families to be able to enjoy it the best way possible with fun, laughter, and free of lice!” stated Maria Botham, Founder and President of the Hair Fairies brand. “This is also a fun way to give back to the community.”

Hair Fairies, The Head Lice Helpers, the country’s leading head lice brand, has been helping millions of families that are stricken with head lice since 1999. To learn more about Hair Fairies salons and locations, their natural products and to order online, visit www.hairfairies.com. Even if you do not have head lice stop by and visit Santa and learn how you can prevent an outbreak in the future! 

HoHoHo… Happy Holidays from the Hair Fairies staff. 

Click here to see all recent news from this company

OTTAWA, ONTARIO–(Marketwire – 6 déc. 2010) – Alors que le Canada songe au renouvellement de son Accord sur les soins de santé en 2014, les principaux intervenants en santé publique sont optimistes quant à la mise sur pied d’un registre national d’immunisation, déclare Debra Lynkowski, présidente-directrice générale de l’Association canadienne de santé publique (ACSP).

« Notre réponse typiquement canadienne aux problèmes d’immunisation plus vastes a malheureusement entraîné des approches diverses au pays », affirme Debra Lynkowski. « Maintenant, alors qu’on approche du renouvellement de l’Accord sur les soins de santé, en 2014, le moment est venu de mettre sur pied un registre national d’immunisation harmonisé. »

Nous reconnaissons qu’une demande de financement supplémentaire auprès des gouvernements peut sembler invraisemblable dans le présent contexte fiscal, mais une stratégie nationale d’immunisation basée sur un registre national, soutenu par toutes les provinces et les territoires, assurerait une protection équitable des Canadiens contre les maladies évitables par la vaccination, et ce, peu importe leur lieu de résidence, leur âge ou leur statut socio-économique.

« Tous les Canadiens devraient avoir un accès égal à l’immunisation contre les maladies évitables par la vaccination. Le lieu de résidence ne devrait pas avoir d’incidence quant à l’accès aux programmes d’immunisation », soutient Debra Lynkowski.

Les améliorations découlant d’une stratégie nationale d’immunisation comprendraient une harmonisation des calendriers de vaccination pour les enfants partout au pays, un alignement de l’introduction des nouveaux vaccins et une égalité d’accès aux vaccins dans toutes les provinces et territoires. La collecte méthodique de données relatives à l’immunisation dans un registre national d’immunisation modernisera la façon dont les autorités transmettent les dossiers d’immunisation des patients et aidera à assurer des taux de couverture suffisamment élevés partout au pays afin de mieux protéger les Canadiens.

Debra Lynkowski souligne qu’une stratégie nationale promouvrait aussi de meilleures possibilités de recherche, la promotion de vaccins, ainsi qu’une meilleure éducation des fournisseurs de soins de santé et du public. À l’heure actuelle, le Canada n’a pas de calendrier harmonisé de vaccination systématique pancanadienne.

« En bref, il vaut mieux prévenir les maladies que d’avoir à les traiter », conclut Debra Lynkowski.

Ces recommandations sont le résultat d’un dialogue continu sans précédent que tiennent les dirigeants du gouvernement et les principaux intervenants de l’industrie et des secteurs de la santé publique et des soins de santé.

Fondée en 1910, l’Association canadienne de santé publique (ACSP) est le porte-parole de la santé publique au Canada. L’indépendance de l’ACSP, ses liens avec la communauté internationale et le fait qu’elle soit la seule organisation non gouvernementale canadienne à se consacrer exclusivement à la santé publique la placent en position idéale pour conseiller les décideurs à propos de la réforme du réseau de santé publique et pour orienter les initiatives visant à protéger la santé individuelle et collective au Canada et dans le monde. Grâce à son effectif diversifié représentant plus de 25 professions, son efficacité démontrée, son approche de collaboration et son envergure nationale, l’ACSP est le chef de file canadien en santé publique. 

Contexte

L’ACSP travaille activement avec les principaux intervenants de l’industrie pour créer un contexte favorable à une stratégie nationale d’immunisation qui protégerait les Canadiens contre les maladies évitables par la vaccination. Pour faciliter un dialogue continu, l’ACSP a organisé une table ronde en 2009 avec les principaux intervenants et a depuis participé à diverses activités d’échange d’information organisées par d’importants organismes nationaux. 

En outre, pour assurer une réponse dans les meilleurs délais à la pandémie H1N1 de l’année dernière, l’ACSP, en collaboration avec l’Agence de la santé publique du Canada, l’Association médicale canadienne, le Collège des médecins de famille du Canada et la Société nationale de spécialistes pour la médecine communautaire, a mis au point l’outil « GRIPPE PANDÉMIQUE H1N1 — Aide-mémoire à l’intention des cliniciens de première ligne ».

En réponse à l’importante demande de renseignements en plus des renseignements déjà offerts par le gouvernement du Canada, l’ACSP a fondé des centres d’échange d’information canadiens sur la grippe H1N1 comme autre source non gouvernementale de renseignements fiables pour les Canadiens.

En tant que secrétariat pour la Coalition canadienne pour la sensibilisation et la promotion de la vaccination, l’ACSP fait office de facilitateur et de coordonnateur d’activités de la Coalition pour réduire au minimum les chevauchements et s’assurer que les Canadiens reçoivent des messages cohérents concernant l’immunisation.

Un document d’information est disponible à l’adresse suivante : http://media3.marketwire.com/docs/cpha-fre.pdf

NANCHANG, CHINA–(Marketwire – Dec. 3, 2010) – Hiru Corporation (PINK SHEETS:HIRU) (www.hirucorporation.com) subsidiary Shuangshi AHP Co. dispatched company representatives to evaluate the agricultural developments and increase company sales in the regions of Ganzhou, Yichun and Jian.

Shuangshi’s assistant general manager and sales manager met with several potential customers in the aforementioned regions to discuss the potential of Shuangshi products on the local markets, as the company works on gaining more exposure with Chinese farmers for their vaccination needs.

The representatives also negotiated with two new agricultural clients, each client reporting annual sales of approximately $30 million USD. Following these negotiations, Shuangshi AHP representatives supplied the customers with new HIRU products for testing and evaluation by the clients. Shuangshi AHP anticipates to gain more new clients as the company’s top quality animal vaccination products gain exposure in the market.

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hiru Corporation that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases “can be,” “expects,” “may affect,” “believed,” “estimate,” “project” and similar words and phrases are intended to identify such forward-looking statements. Hiru Corporation cautions you that any forward-looking information provided by or on behalf Hiru Corporation is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hiru Corporation’s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hiru Corporation’s control. In addition to those discussed in Hiru Corporation’s press releases, public filings, and statements by Hiru Corporation’s management, including, but not limited to, Hiru Corporation’s estimate of the sufficiency of its existing capital resources, Hiru Corporation’s ability to raise additional capital to fund future operations, Hiru Corporation’s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hiru Corporation’s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hiru Corporation does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

MADISON, WI–(Marketwire – December 1, 2010) –  TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for the treatment of cancer and other diseases, today announced that it is the exclusive sponsor of the American Cancer Society’s Fall 2010 Matching Grant Challenge, a national fundraising campaign that was launched in November.

As sponsor, TomoTherapy will contribute $1 for every $1 donated by the general public, up to $100,000, to support the American Cancer Society’s efforts to help people stay well and get well from cancer, find cures, and fight back against the disease. The Matching Grant Challenge ends on December 15, 2010.

“Every day, TomoTherapy’s innovative radiation therapy solution helps patients fight cancer. With our support of the American Cancer Society, we extend our impact beyond technology,” said Fred Robertson, M.D., TomoTherapy’s CEO. “In matching the generous contributions of individuals, TomoTherapy proudly strengthens the efforts of the American Cancer Society — from funding groundbreaking research to providing resources for patients, their families and caregivers at every step in the cancer experience.”

About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy^® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art^® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD^™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile^™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

HUDSON, NY–(Marketwire – December 1, 2010) – Taconic, a leading provider of in vivo solutions to life science researchers worldwide, announced that its Cologne, Germany production program has earned accreditation from AAALAC International (the Association for Assessment and Accreditation of Laboratory Animal Care International). With this accreditation, all Taconic programs worldwide are now AAALAC accredited thereby assuring customers that Taconic meets the highest industry standard of quality, health, genetic integrity and care for its animal models.

AAALAC International promotes the humane treatment of animals in science through voluntary accreditation and evaluation programs. Taconic was one of the first suppliers to be accredited by AAALAC International in 1969.

“For more than four decades, through our voluntary participation in the AAALAC accreditation process, Taconic has demonstrated its commitment to the safe, humane treatment of the research animals that are vital to our clients’ biomedical research,” said Jeffrey J. Lohmiller, DVM, MS, ACLAM, Global Senior Director, Veterinary Sciences, Taconic. “Attaining AAALAC accreditation across all of our programs worldwide is an achievement that reflects Taconic’s unwavering focus on quality and accountability.” 

The rigorous accreditation process required both a stringent internal review by Taconic and a comprehensive, on-site assessment by AAALAC evaluators, reviewing the Cologne site’s entire animal care and use program. To maintain their accredited status, all Taconic programs undergo re-evaluation every three years as per AAALAC requirements.

According to AAALAC International, more than 800 companies, universities, hospitals, government agencies and other research institutions have earned this prestigious accreditation.

About Taconic
Taconic is a leading provider of life sciences solutions to researchers worldwide, offering innovative lab animal models and scientific services that facilitate in vivo studies and advance drug discovery. Taconic’s wide range of advanced solutions include custom genetically modified rat and mouse model generation and production, contract breeding, off-the-shelf model repositories, compound profiling, contract research, imaging, genetic monitoring and health testing. Headquartered in New York’s Hudson River Valley, Taconic operates seven breeding facilities and three service laboratories in the U.S. and Europe and maintains a staff of over 1,000 scientific specialists committed to technological innovation. Additional information about Taconic is available at www.taconic.com.

PLYMOUTH MEETING, PA–(Marketwire – November 29, 2010) – In advance of the first randomized, placebo-controlled clinical trial in the world of its type for Alzheimer’s disease and other dementias, Quietmind Foundation (QMF), Plymouth Meeting, Pa., is honored to host two presentations by Gordon Dougal, M.D., a National Health Service physician, inventor, and dementia researcher from Durham, U.K. Dr. Dougal will discuss the application of 1072nm infrared light therapy in the treatment of dementia. The presentations will include the pioneering research findings from studies conducted by Dr. Dougal’s colleagues at Durham University on the effects of this type of phototherapy on neuroprotection and beta amyloid plaque deposition and abeta42 oligomer levels.

Professional colleagues, caregivers, and family members of people struggling with neurodegenerative disorders are cordially invited. The free programs will take place on Sunday, December 12, from 4:00 p.m. to 5:30 p.m., and Monday, December 13, from 11:30 a.m. to 1:00 p.m., at the QMF offices, 521 Plymouth Rd., Suite 111, Plymouth Meeting, Pa., 19462. Light refreshments will be served.

Each program will begin with a brief scientific overview by Dr. Dougal directed toward professionals working in research and clinical care of people struggling with dementia. Marvin Berman, Ph.D., QMF’s president, will then discuss the foundation’s previous research in dementia and current clinical work. Following will be a demonstration of the 1072nm infrared light therapy and overview of parameters of the clinical trial to be conducted at the QMF offices.

For a fuller description of the upcoming clinical trial utilizing the 1072nm technology for the treatment of early stage dementia: http://clinicaltrials.gov/ct2/show/NCT01059877?term=1072&rank=3

About Quietmind Foundation

Quietmind Foundation, a 501(c)3 nonprofit founded in 2000, is an international center for cutting-edge research and consultation in the use of brainwave (EEG) biofeedback and related technologies. Its ongoing research agenda — and the nondrug, noninvasive treatments offered through its affiliate, Quietmind Associates — focuses on the spectrum of neurodegenerative disorders, including dementia, Parkinson’s, ALS, and MS as well as traumatic brain injury, PTSD, and learning disabilities. Its goal is to integrate innovative technologies and evidence-based behavioral interventions into governmental, public health, and educational service delivery systems.

QMF’s prior research on Alzheimer’s disease was accepted for presentation at the July 2009 International Conference on Alzheimer’s Disease (ICAD) in Vienna, Austria. This research demonstrated improvements in subjects’ memory, executive function, and psychiatric symptoms, and a reduction in medications.

For further information and reservations for either presentation: 610-940-0488 or [email protected]

Click here to see all recent news from this company

ALEXANDRIA, VA–(Marketwire – November 26, 2010) – Mortality rates for people with type 1 diabetes are decreasing, but overall remain seven times higher than those of the general population — likely as a result of long-term complications, a study in the December issue of Diabetes Care reports.

And while there were no significant differences in mortality rates between genders, women with type 1 diabetes were 13 times more likely to die than women who did not have diabetes, reported researchers from the University of Pittsburgh. Also in this study, part of the Epidemiology Research International Study Group, a much higher proportion of African Americans (50.6 percent) died than Caucasians (24 percent).

“It’s unclear why, for both women and African Americans, type 1 diabetes has such a major effect compared to the general population,” said Dr. Trevor Orchard, senior author of the study. “This greater effect of diabetes for women is not seen as strongly in studies in other parts of the world. One thing that is clear is that we need to pay special attention to their care and treatment and continue to investigate why they might be disproportionately impacted by the long-term consequences of this disease.”

Overall, mortality rates for people with type 1 diabetes fell significantly in this community-based population from Allegheny County, PA, over the past several decades, the study found. For those diagnosed between 1965 and 1969, mortality rates were 9.3 times higher than the general population. However, for those most recently diagnosed (1975-1979), the rate was just 5.6 times higher, showing a clear decline.

“It looks like the main improvement in those most recently diagnosed is related to dramatically reducing mortality in the first five years after diagnosis,” said Dr. Aaron Secrest, lead author of the paper. “We think it’s probably a result of better management and awareness of diabetes control, leading to providers and patients doing a better job of monitoring for acute complications.”

Overall, reductions in mortality are most likely due to the tremendous improvements in treatment and care during the 1980s and 1990s, the researchers noted. In particular, blood glucose self-monitoring, A1C testing and use of new blood pressure medications such as angiotensin-converting enzyme inhibitors, which also help protect against diabetic kidney disease. These changes have greatly improved both blood sugar and blood pressure control, often the cause of life-threatening complications.

The study looked at people in Allegheny County the Pittsburgh area who had type 1 diabetes diagnosed as a child between 1965 and 1979 and at the time of analysis had a duration of diabetes between 28 and 43 years, and explored differences in mortality based on sex, race (Caucasian vs. African American) and year of diagnosis.

For more information, please contact Dr. Trevor J. Orchard, University of Pittsburgh, Department of Epidemiology, Graduate School of Public Health, at email: [email protected] or call 412-383-1032.
To contact Dr. Aaron Secrest call 940-597-1991.

Diabetes Care, published by the American Diabetes Association, is the leading peer-reviewed journal of clinical research into one of the nation’s leading causes of death by disease. Diabetes also is a leading cause of heart disease and stroke, as well as the leading cause of adult blindness, kidney failure, and non-traumatic amputations.

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>

MADISON, WI–(Marketwire – November 23, 2010) – TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for the treatment of cancer and other diseases, today announced availability of a shielding solution that enables hospitals and cancer centers to quickly, easily and inexpensively build out treatment vaults that are properly shielded for use of the TomoTherapy^® radiation therapy system. The Total Shield^™ by NELCO, the worldwide leader in designing, manufacturing, and installing specialized products and services for the medical, industrial, and construction fields, is a customized shielding enclosure designed to fit around a TomoTherapy unit, making it possible for the radiation therapy system to be placed into existing under-shielded vaults or other treatment rooms where there may not be enough space to install necessary shielding using the existing infrastructure.

Total Shield provides hospitals and cancer centers with the flexibility to put the TomoTherapy system in an existing space, which may be too small or may not include enough shielding for modern intensity-modulated radiation therapy (IMRT) devices. Instead of adding shielding in the walls, the Total Shield enclosure is designed to wrap around the TomoTherapy system itself.

By taking this approach, TomoTherapy customers can potentially save hundreds of thousands of dollars in shielding costs and eliminate the months it takes to install conventional shielding solutions. Total Shield can be installed in just a matter of days. Additionally, because the Total Shield can be easily removed, it can be reused if the TomoTherapy system is eventually moved to a new location.

“Total Shield is the most recent example of how the TomoTherapy system’s unique design, and its small footprint, can allow hospitals and cancer centers to easily adopt cutting-edge cancer care technology in places where other solutions are not feasible,” said Harry Freeman, director of commercial operations at TomoTherapy. “Combined with the TomoTherapy system’s integrated beam stop technology, Total Shield can dramatically reduce the cost of building out a vault with extensive shielding, and enables facilities to get their TomoTherapy system up and running much quicker than other radiation treatment solutions.”

Total Shield was designed collaboratively by NELCO and will be on display in the TomoTherapy booth (#6406) at RSNA 2010, November 28 – December 3, at McCormick Place in Chicago, Illinois.

About NELCO 
NELCO, an ISO 9001:2008 certified company, is an industry leader in the design, manufacturing, and installation of specialized products and services, for the medical, industrial, and construction fields. Such products include shielding for medical radiation therapy, medical diagnostic imaging, anti-corrosive linings, and industrial radiation shielding. With offices around the US, United Arab Emirates, the United Kingdom and China, NELCO always has a facility nearby, cutting shipping costs, and helping excel in customer service. For more information, visit http://www.nelcoworldwide.com, or call 1-781-933-1940.

About TomoTherapy Incorporated 
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy^® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions includes its flagship Hi·Art® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoHD, TomoDirect, TQA, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

FORT COLLINS, CO–(Marketwire – November 23, 2010) – Available for various BlackBerry^® smartphones, the pink OtterBox^® “Strength” line now offers protection for the BlackBerry^® Torch^™ 9800 smartphone. These innovative Commuter Series^® cases are a stylish way to keep the BlackBerry Torch smartphone pristine while supporting a good cause. OtterBox donates 10 percent of the purchase price from each “Strength” case to the Avon Breast Cancer Crusade to support research to find a cure for breast cancer and programs that provide access to breast health care, regardless of a person’s ability to pay.

“Supporting the Avon Breast Cancer Crusade has been an amazing opportunity for OtterBox and our customers,” said OtterBox founder and CEO Curt Richardson. “We’ve enjoyed the reveal of each new ‘Strength’ case and to date have donated more than $80,000 to the cause.”

The OtterBox Commuter Series case for the BlackBerry Torch smartphone is unlike any other case on the market, providing customized layers for extra protection. First, a white silicone skin fits snuggly around the back with plugs that fit precisely into all ports to prevent damage from dirt and dust. Second, a pink polycarbonate shell snap onto the front and another piece to the back allowing full functionality of the phone’s sliding feature and touch screen. The case also includes a self-adhering screen protector to keep the display scratch free.*

See the complete pink line for all you BlackBerry smartphones, available at www.otterbox.com/strength. 

Additional information for OtterBox Commuter Series for the BlackBerry Torch 9800 smartphone:

Environmental Protection:

• Added protection against bump and shock

Colors:

• Silicone: white
• Polycarbonate: pink

Dimensions (case only):

• 4.56″ (115.71 mm) x 2.64″ (67.11 mm) x 0.72″ (8.28 mm)

Approximate Weight (case only):

• 0.80 oz (22.68 g) 

About the Avon Breast Cancer Crusade:

The Avon Foundation for Women’s Avon Breast Cancer Crusade has supported programs in more than 50 countries since its creation in 1992 and to date has raised and awarded more than $640 million worldwide for advancing access to care and finding a cure for breast cancer, with a focus on the medically underserved. Funding supports five areas: awareness and education; screening and diagnosis; access to treatment; support services; and scientific research. For more information or free printable breast cancer information, visit www.avonfoundation.org. For information about participating in the Avon Walk for Breast Cancer events, visit www.avonwalk.org.

About OtterBox:

Built upon fundamentals of hard work, innovation and perseverance, OtterBox is a leader in the production of premier protective solutions for global handheld manufacturers, wireless carriers and distributors.

Incorporating creativity and cutting-edge design into every product, OtterBox creates sleek and durable cases that offer reliable device protection to complement any lifestyle.

OtterBox was founded in 1998 and is headquartered in Fort Collins, Colo.

For more information, visit www.otterbox.com or call 888-695-8820. We’ve Got Technology Covered.

Notes:

*Commuter Series cases NOT protected against water. Will provide some added protection against bump and shock.

The BlackBerry and RIM families of related marks, images and symbols are the exclusive properties and trademarks of Research In Motion Limited.

©2010 Otter Products, LLC. All rights reserved. OtterBox and all OtterBox logos, trademarks and symbols are the property of Otter Products, LLC.

Click here to see all recent news from this company

SANTA MONICA, CA–(Marketwire – November 22, 2010) – The first annual Grayson’s Gift Foundation Event, hosted on November 11, 2010, was a huge success, raising more than $150,000. The charity event took place in the ballroom at Hotel Casa del Mar in Santa Monica.

Grayson’s Gift Foundation is a non-profit committed to raising money for the brain cancer research department at the Children’s Hospital of Los Angeles. Money was raised through ticket sales, an extravagant silent auction, and generous donations made by attendees.

The Grayson’s Gift Foundation was founded in 2010 by Leslie and Cliff Katab, whose son Grayson died from a brain tumor just over two years ago. Cliff Ketab said, “We went through many surgeries and chemo and countless days in hospitals, as well as traveling to Europe for experimental treatments. Although we did everything humanly possible, we lost our beloved baby boy two years ago.

“Pediatric brain cancer is the second leading cause of children’s death only behind social causes (car accidents, etc). Being immersed in this world taught us many life lessons. One thing we know is that we must help find a cure for these children. We created Grayson’s Gift Foundation just for this reason. Our charity donates its contributions directly to support research and training for pediatric brain cancer.”

A festive evening, it was a fusion of determined oncologists, compassionate celebrities, friends and family. Thrown into the mix were individual demonstrations of state-of-the-art brain-computer controlled games using NeuroSky technology. The day before the event, NeuroSky donated several games to the pediatric cancer ward at Children’s Hospital Los Angeles. At the event, David Westendorf, Vice President of NeuroSky, talked about how Children’s Hospital LA saved his niece’s life, and then he gave away NeuroSky-powered Mindflex games from Mattel as table prizes.

Celebrity guests included: actor Jonathon Goldsmith, recognized as “The Most Interesting Man in the World” in recent Dos Equis commercials; Corey Feldmen of “The Goonies”; Taylor Armstrong of Bravo’s “Real Housewives of Beverly Hills”; Vienna Girardi who starred in ABC’s “The Bachelor”;” Jennifer Elise Cox, known for her appearance in The Brady Bunch Movie; actress Delphine Chaneac; and actor James Preston of “The Gates.”

Photos: http://www.ballantinesbiz.com/Green_Oct_2010/CHLA/CHLA_GraysonsGift_112210.html

Click here to see all recent news from this company

CINCINNATI, OH–(Marketwire – November 22, 2010) – In the midst of flu season, millions of Americans are rushing to get vaccinated before becoming one of the approximately 200,000 flu victims the Centers for Disease Control (CDC) estimates are hospitalized every year. They aren’t the only ones suffering: according to study findings presented in a 2006 CNN story, the flu and other infectious disease outbreaks cost the nation’s employers about $10 billion a year.

That’s why the University of Cincinnati’s Midwest Center for Emerging Infectious Diseases (MI-CEID) exists. The center serves as a touchstone for advanced medical breakthroughs to provide protection and preparedness for biological events throughout the country — including bioterrorism, biological threats, pandemic outbreaks and even seasonal flu viruses.

“The best way to head off potential public health disasters is to have a targeted means to prevent, quickly diagnose, contain and treat infections. This can only be possible through diligent and comprehensive interdisciplinary research,” said Malak Kotb, Ph.D., chair of the department of molecular genetics, biochemistry and microbiology at the University of Cincinnati College of Medicine, and senior career research scientist at the VA Medical Center.

The MI-CEID is a unique model for collaboration across diversified medical disciplines, including:

• UC Academic Health Center;
• Local hospitals including the Cincinnati Children’s Hospital Medical Center;
• Environmental Protection Agency (EPA);
• VA Medical Center;
• Regional health department;
• Public safety agencies;
• Community leaders;
• Professional associations.

“Solutions to disease treatment and prevention require innovation — and you can’t be innovative and be in silos. We achieve the best outcomes by utilizing teams of people who are skilled in their areas of knowledge,” said Kotb. “By doing this, we create something novel and effective. We need to be ahead of the curve, and at UC we have the capabilities and technology to be able to make these strides in healthcare.”

Kotb credits the cross-disciplinary nature of UC’s research facility as key to the center’s early and continued successes. Whereas similar research centers rely on collaborators that may be spread across the country, the MI-CEID brings researchers from each of the organizations above, plus the university’s College of Medicine, under one roof for optimal communication and exchange of ideas and expertise.

To combat potential health threats, the collaborative team uses a state-of-the-art approach to identify and study different types of infectious bacteria, viruses and toxins to improve their detection. The team is also conducting research to identify genetic markers that may predict disease severity in individual patients and inform the most beneficial treatment for each based on genotypes of their DNA. 

“Once we find which genes are engaged in the disease process, we can determine how they are connected through the biological networks that influence disease,” said Kotb. “This allows us to create a roadmap that can predict responses, increase protection, reduce the severity or prevent the illness or disease altogether. This helps save time, money and lives when outbreaks occur.”

Organizations have been quick to realize the potential of the MI-CEID: the National Institutes of Health (NIH), the Department of Defense and Homeland Security, the Defense Threat Reduction Agency (DTRA) and other government agencies have tapped the center for research projects with national implications. In addition, Kotb cites the importance of private support via UC’s billion-dollar Proudly Cincinnati fundraising campaign. The center also relies on corporations that contribute to the research center’s ability to remain operational year-round and expand on its research capabilities.

But while this support can fund specific research initiatives, Kotb says that funding for truly cutting-edge research can sometimes be scarce. Financial support and partnerships are always being sought to further support research and discovery, build a stronger infrastructure, and attract high caliber scientists to effectively fight existing and emerging pathogens. These activities create jobs and boost the economy.

“Private industry is an essential ingredient to successful disease-mitigation and prevention strategies. Without private support to spur on ground-breaking research, essential studies –including those that can predict infection severity in different patients and/or can help suggest the best treatment strategies, and/or predict adverse reactions to certain drugs or vaccines can certainly save lives and reduce medical costs,” Kotb said.

There will always be another pandemic disease or public health scare, but with the UC’s MI-CEID program unique vision and collaborative model the treatments will be more timely and effective. For more information on this innovative program, visit www.uc.edu.

About the University of Cincinnati
 Ranked by the National Science Foundation among the top 20 public, urban research universities in the United States, the University of Cincinnati is the region’s largest employer, with a diverse student population of more than 39,000. UC’s faculty has distinguished themselves worldwide for their creative teaching and research, including members of the National Academy of Science, Institute of Medicine and winners of Tony, Grammy and Pulitzer Prizes. The University’s 15 Colleges set the foundation for a university dedicated to undergraduate, graduate, and professional education, experience-based learning, and research. U.S. News has described UC as one of 15 “up and coming” universities and Forbes Magazine named UC one of the world’s most beautiful campuses.

About the University of Cincinnati Foundation
The University of Cincinnati Foundation is leading Proudly Cincinnati: Tower of Strength, Rock of Truth, the University’s most ambitious campaign in history, supporting the vision for UC to become the finest urban research university in the United States. Proudly Cincinnati’s goal is to raise $1 billion by 2013. To date, approximately $696 million has been raised for scholarships, innovative teaching and groundbreaking research. For more information about the Proudly Cincinnati campaign, visit www.uc.edu/foundation.

The University of Cincinnati Foundation
University Hall, Suite 100
51 Goodman Drive
Cincinnati, OH 45219
www.ProudlyCincinnati.org
www.Twitter.com/ProudlyCincy
www.Facebook.com/ProudlyCincinnati

id=”nav_links”>

TUSTIN, CA–(Marketwire – November 22, 2010) – November is American Diabetes Month and Integrium LLC, a Contract Research Organization (CRO) with a therapeutic focus on cardiovascular and metabolic diseases, is at the forefront of clinical research to improve diabetes treatment. Eileen McAuley, Chief Operating Officer of Integrium, explains that the company has conducted 18 clinical trials of interventions for diabetes at 557 study sites. In addition to trials targeting diabetes, Integrium has conducted more than 100 cardiovascular and renal disease trials, which have an impact on diabetes care since diabetes is a leading cause of kidney failure and more than two-thirds of people with diabetes die of heart disease or stroke.

Integrium’s dedicated team of clinical researchers specializing in diabetes has pioneered therapies to improve the quality of life for people living with diabetes. Integrium’s Director of Project Management and Field Operations, Liza Moore, heads up a team with special expertise in wound healing. She explains that diabetic foot ulcers are among the most serious complications of the disease and untreated, often result in infection and amputation. “Our experience encompasses not only drugs to help manage blood glucose, but also medical devices such as bioengineered tissue products to speed wound healing. We are interested in preventing complications and effective treatment for those that can not be prevented.”

Integrium founder Dr. David H. G. Smith observes that the diabetes epidemic is not limited to the U.S. “One of our recent diabetes trials followed subjects in India, which has the largest diabetes population in the world, as well as subjects in the United States.” With its global reach, Integrium has completed trials in North America, Central and South America, the European Union and Asia for 12 of the top 20 biopharmaceutical companies.

About Diabetes
The United States is in the throes of a diabetes epidemic. An estimated 24 million children and adults have diabetes. Another 57 million others have pre-diabetes, elevated blood glucose levels that increase their risk of developing diabetes, heart disease and stroke.

One in ten American adults has diabetes and the Centers for Disease Control and Prevention (CDC) say that number could triple in the coming decades. The disease is the seventh leading cause of death in the U.S. and it is likely to be underreported as a cause of death.

Diabetes is a leading cause of kidney failure, blindness, amputations and pregnancy complications. Tighter blood glucose control reduces the symptoms and life-threatening complications of diabetes.

About Integrium, LLC
Integrium is a full-service clinical research organization (CRO) designing, conducting, and analyzing clinical trials for pharmaceutical research in dermatology, cardiovascular and metabolic disorders. It is committed to focused, specialized and long-term personalized service to its partners. It has a strong reputation for delivering high-quality management of clinical development programs. Combining the Integrium Clinical Excellence (ICE) study start-up and management methodology and therapeutic expertise leads sponsors to more confident, better-informed drug and device development decisions. For more information please visit www.integrium.com.

BOCA RATON, FL–(Marketwire – October 26, 2010) – David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that the Company has received approval from the Institutional Review Board (IRB) at the University of Mississippi Medical Center for a study to assess concussions in competitive athletes using its PD2i Analyzer™. The study will be conducted in collaboration with the University of Mississippi Medical Center (UMMC) and Belhaven University. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i^® nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that accurately risk stratify specific target populations for future pathological events, including congestive heart failure patients for cardiac death resulting from arrhythmia or pump failure, diabetics for diabetic autonomic neuropathy (DAN), and trauma victims for imminent death absent immediate lifesaving intervention.

“We’re pleased to have approval from UMMC’s IRB permitting us to commence this important study of concussion status in competitive athletes — a first for the PD2i Analyzer™. Being able to effectively assess the extent of a concussion and risk of follow-on pathological events in athletes will enable all involved in assessing the extent of harm incurred during competitive play to better determine player need for advanced care and/or player ability to continue to play unharmed. With this approval, we will begin enrolling patients for this important and exciting clinical research study with an NCAA school, which could lead to other similar studies in the future,” stated Mr. Fater.

The IRB reviews research to ensure that the federal regulations for protecting human research participants outlined in UMMC policy, the Department of Health and Human Services (DHHS) regulations (45 CFR 46) and the Food and Drug Administration (FDA) regulations (21 CFR Parts 50 & 56), as well as other requirements, are met. 

About Vicor Technologies, Inc.
Vicor Technologies is a biotechnology company creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i^®). The PD2i^® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.

Vicor currently has three products employing the PD2i^® nonlinear algorithm. The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability; physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research, risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in multiple clinical trials, identifies patients at risk of cardiac death.

Vicor anticipates additional applications employing the PD2i^® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

Disclaimer
The appearance of name-brand institutions, such as the University of Mississippi Medical Center Institutional Review Board, NCAA, and the U.S. Army Institute for Surgical Research, in this media release does not constitute endorsement by institutions of the information, products or services contained therein.

Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to successfully complete the normal range study for PD2i^®values; our ability to generate revenues from the sale of the PD2i Analyzer™; our ability to obtain FDA approval of our 510(k) submission to secure a claim for the PD2i CA™(Cardiac Analyzer) for assessing patients undergoing tests for cardiovascular disease and our ability to obtain marketing clearance from the FDA for the PD2i VS™ (Vital Sign) for military and civilian applications; our ability to develop additional applications for the PD2i^®algorithm; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 10-21

Click here to see all recent news from this company

EDMONTON, ALBERTA–(Marketwire – Oct. 21, 2010) – Medtronic, Inc. (NYSE:MDT) announced today the Canadian launch of a novel technology designed to provide additional protection against the risks associated with hypoglycemia. This new device, currently available in more than 50 countries outside of the United States and now in Canada, can automatically suspend insulin delivery when the device senses that glucose levels have fallen to or below a pre-selected threshold. This feature is intended to reduce the severity of low blood sugar (hypoglycemia) in situations where patients ignore or are unable to treat hypoglycemia. Hypoglycemia, a dangerous and often frequent occurrence with diabetes, can be one of the most frightening aspects of living with type 1 diabetes. If left untreated, hypoglycemia can cause loss of consciousness, seizure, coma, or even death.¹

Research indicates that, on average, a person with diabetes will experience more than one low blood sugar event every two weeks. Additionally, each year, nearly one in 14 people with insulin-treated diabetes will experience one or more episodes of severe hypoglycemia, requiring urgent treatment by a healthcare professional.² A third of diabetes patients suffer from hypoglycemia while asleep, which may impair their ability to recognize or act to prevent a serious episode.³ An estimated 33 percent of diabetes-related deaths are a result of acute complications such as hypoglycemia.⁴ While most patients experience “warning signs” before a hypoglycemic event (such as feeling shaky, sweating, tingling in the lips, confusion and irritability), many others may not experience any warning signs at all.

“The Paradigm Veo, with its automatic feedback mechanism, is a major step forward in our commitment to improving glucose control in diabetics,” says Katie Szyman, president of the Diabetes business and senior vice president at Medtronic. “While not a cure for diabetes, we believe this automatic feature offers added protection, greater confidence and may lower the risk of injury associated with hypoglycemic events. Equally important, it will give patients and family members more peace of mind.”

The Paradigm Veo System includes an insulin pump with a continuous glucose monitoring (CGM) system (provided by means of a separate sensor and transmitter). The patient uses readings from the monitor to understand their current glucose level changes. Based on confirmatory fingerstick blood glucose measurements, the patient then programs the insulin pump to deliver an appropriate amount of insulin. Insulin combats high blood sugar, a key cause of heart disease and other long-term complications in type 1 diabetes.¹ However, if data transmitted from the sensor show the patient’s glucose levels have dropped below a defined threshold, the device alarms to alert the patient. If these alarms are ignored, the insulin pump automatically suspends insulin delivery for up to two hours. This helps to protect against potentially dangerous hypoglycemic events. 

“This latest technology is a significant advance that will help people with diabetes to more safely optimize glucose control. In order to reduce the long-term risk of diabetes-related complications, which can cause blindness, kidney failure and heart attacks, patients should manage their glucose levels to as near normal as possible. Unfortunately, aggressive glucose control can increase the risk of severe hypoglycemia, which can render a patient unconscious—and if recurrent—can have very serious consequences,” says Dr. Bernard Zinman, Director of the Leadership Sinai Centre for Diabetes at Mount Sinai Hospital in Toronto. “For the first time, an insulin pump can now not only warn the patient of this dangerous situation but can also respond and thus help correct this undesirable situation. The Paradigm Veo alerts patients if their glucose levels drop too low, and stops the delivery of more insulin if they don’t respond to the alert. Having this safety feature may allow patients greater control over severe hypoglycemia.”

About the Diabetes Business at Medtronic

The Diabetes business at Medtronic (www.medtronicdiabetes.ca) is the world leader in advanced diabetes solutions, including integrated diabetes management systems, insulin pump technology, continuous glucose monitoring systems and management software, as well as world-class, 24/7 expert consumer and professional service and support.

About Medtronic

Medtronic, Inc., headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health and extending life for millions of people around the world. More information is available at: www.medtronic.com.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

About Medtronic of Canada Ltd.

Medtronic of Canada sells, services and distributes Medtronic products in Canada: medical devices used in cardiovascular medicine, diabetes, spinal and neurosurgery, and ear, nose and throat surgery. Medtronic of Canada employs over 420 Canadians, it is headquartered in Brampton, Ontario, has an Operations Centre in Mississauga and regional offices in Vancouver and Montreal and an atrial fibrillation (AF) ablation catheter manufacturing facility – Medtronic CryoCath – in the Montreal metropolitan area.

References

1. Diabetes UK: http://www.diabetes.org.uk/Guide-to-diabetes/Complications/Hypoglycaemia/ (Accessed 23^rd April 2009)

2. Leese GP, Wang J et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes. Diabetes Care 26:1176-1180, 2003.

3. Pramming S, Thorsteinsson B et al. Nocturnal hypoglycemia in patients receiving conventional treatment with insulin. British Medical Journal 291(1985):376-379

4. Orchard TJ. International evaluation of cause-specific mortality and IDDM. Diabetes Care 14:55-60, 1991